Categories AlphaGraphs, Earnings, Health Care
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for fiscal 2023.
The Indianapolis-based pharmaceutical company said its revenues declined 11% year-over-year to $6.96 billion in the first quarter, hurt by lower realized prices and a decline in volumes.
The weak top-line performance translated into a 38% fall in net earnings, on an adjusted basis, to $1.62 per share. Unadjusted profit decreased to $1.34 billion or $1.49 per share from $1.90 billion or $2.10 per share in the first quarter of 2022.
“Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity,” said David Ricks, CEO of Eli Lilly.
Prior Performance
Most Popular
Important takeaways from Conagra Brands’ Q3 2025 report
Conagra Brands, Inc. (NYSE: CAG) has reported weaker-than-expected revenue and profit for the February quarter, with sales declining across all business segments amid softer demand and persistent supply challenges. The
Main takeaways from Lamb Weston’s (LW) Q3 2025 earnings report
Shares of Lamb Weston Holdings, Inc. (NYSE: LW) jumped 9% on Thursday after the company delivered better-than-expected results for the third quarter of 2025 and reaffirmed its outlook for the
Summary: Tesla (TSLA) reports Q1 2025 production, deliveries
Tesla Inc. (NASDAQ: TSLA) has announced results of vehicle production and deliveries for the first quarter of 2025. The company also provided data on the deployment of energy storage products
